Abstract:
:The aim of this study was to assess the response of social phobia (SP) symptoms to methylphenidate (MPH) treatment in children with attention deficit hyperactivity disorder (ADHD). Twenty-one ADHD patients with SP, aged between 8 and 18 years, received 12 weeks of MPH treatment. The severity of SP symptoms were assessed by the Liebowitz Social Anxiety Scale for Children and Adolescents (LSAS-CA), and the severity of ADHD symptoms was assessed by the ADHD Rating Scale at baseline and at endpoint. MPH treatment was associated with a significant decrease in the ADHD Rating Scale scores (P<0.0001) and in the total LSAS-CA scores (P=0.013), as well as the school-related items of LSAS-CA (P=0.011). A significant correlation was found between the reductions in ADHD score and total LSAS-CA score (P=0.038), especially in school-related SP. The improvement in ADHD symptoms because of MPH treatment correlates with a parallel improvement in SP. MPH treatment appears to be safe and effective in ADHD/SP children.
journal_name
Int Clin Psychopharmacoljournal_title
International clinical psychopharmacologyauthors
Golubchik P,Sever J,Weizman Adoi
10.1097/YIC.0000000000000029subject
Has Abstractpub_date
2014-07-01 00:00:00pages
212-5issue
4eissn
0268-1315issn
1473-5857journal_volume
29pub_type
杂志文章abstract::Using spectral analysis of heart rate, several studies have shown that panic disorder patients are characterized by a reduced heart rate variability (HRV), indicative of abnormalities in autonomous nervous system (ANS) function. We recently reported that patients with panic disorder, who did not respond to pharmacothe...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/00004850-200203000-00005
更新日期:2002-03-01 00:00:00
abstract::Negative symptoms are a key feature of schizophrenia. Novel (atypical) antipsychotic drugs, unlike conventional antipsychotics, cause substantial reductions in Positive and Negative Symptom Scale (PANSS) scores. Negative symptoms, however, can arise from both the pathology of the disease (primary negative symptoms) an...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:10.1097/00004850-199803003-00008
更新日期:1998-03-01 00:00:00
abstract::The objective of this paper was to assess the effects of switching from typical and/or atypical antipsychotics to ziprasidone, owing to inadequate response or intolerance, in chronic schizophrenic patients. A total of 312 patients were switched to an 8-week, open-label, flexible dose (40-160 mg/day) of ziprasidone. Ps...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/YIC.0b013e3282f94905
更新日期:2008-07-01 00:00:00
abstract::This analysis characterizes patients with schizophrenia or schizoaffective disorder treated with risperidone who met remission criteria. In a 50-week, open-label trial, stable patients received long-acting injectable risperidone every 2 weeks. Remission criteria included severity (absent-mild ratings on core symptoms ...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/01.yic.0000224791.06159.88
更新日期:2007-01-01 00:00:00
abstract::The DIABCARE Q-Net project developed a complete and integrated information technology system to monitor diabetes care, according to the gold standards of the St Vincent Declaration Action Program. This is the first Telematic platform for standardized documentation on medical quality and evaluation across Europe, which...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/00004850-200104003-00002
更新日期:2001-04-01 00:00:00
abstract::Predicting the outcome of treatment with neuroleptics and understanding the factors that contribute to variability in the response to these drugs have preoccupied researchers and clinicians since the class was developed. Clinicians need empirically based prospective criteria in order to choose a treatment strategy tha...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:10.1097/00004850-199605002-00008
更新日期:1996-05-01 00:00:00
abstract::Good evidence now exists for a therapeutic action of carbamazepine (CBZ) both in acute mania and in the prophylaxis of manic depression. Comparison with other existing therapies and incidence of adverse effects in psychiatric patients also deserve more clinical research. This paper reviews these clinical issues and th...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:10.1097/00004850-198807000-00001
更新日期:1988-07-01 00:00:00
abstract::The aim of this study was to evaluate flexibly dosed brexpiprazole for early-episode schizophrenia through the assessment of efficacy, social functioning, and tolerability. This was an exploratory, 16-week, open-label, flexible-dose (1, 2, 3, or 4 mg/day; target dose 3 mg/day) study in outpatients with early-episode s...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/YIC.0000000000000140
更新日期:2016-11-01 00:00:00
abstract::Although the effects of atypical antipsychotics with regard to improving neurocognitive function are not sufficiently high. The present study applied an atypical antipsychotic monotherapy for patients with acute schizophrenia to (1) examine the percentage of patients who respond well to this treatment, (2) explore the...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/YIC.0000000000000293
更新日期:2020-03-01 00:00:00
abstract::We aimed to construct and assess the psychometric properties of the My Medicines and Me Questionnaire (M3Q), a self-report side-effect questionnaire for mental health patients. Thirty individuals taking a psychotropic medication completed the M3Q side-effect checklist along with the Liverpool University Neuroleptic Si...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/YIC.0000000000000072
更新日期:2015-07-01 00:00:00
abstract::The therapeutic concentrations of antipsychotic drugs in the patient's plasma water or spinal fluid are identical to their blocking potencies in vitro at the dopamine D2 receptor, with the exception of clozapine which acts at D4. The variation in K values between laboratories stems from the fact that the apparent K va...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:
更新日期:1995-09-01 00:00:00
abstract::Fourteen cases of depression resistant to multiple treatments were treated by lithium augmentation of fluoxetine. Tolerability of the treatment was poor. Lithium and fluoxetine may be a possible treatment for resistant depression but there is caution regarding tolerability and toxicity with the relatively high doses o...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/00004850-199400910-00005
更新日期:1994-04-01 00:00:00
abstract::In a total population of patients with a schizophrenic syndrome, the amount of antipsychotic drugs during a defined period was studied. Doses of antipsychotics were higher in males than in females, low to moderate in most patients, and decreased with the duration of illness. There was a significant negative correlatio...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/00004850-199612000-00005
更新日期:1996-12-01 00:00:00
abstract::C-reactive protein (CRP) is an inflammatory marker associated with obesity, insulin resistance, and cardiovascular disease. A recent study found CRP levels to be higher in individuals treated with certain antipsychotic medications such as olanzapine; however, it is not clear whether this is associated directly with dr...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/YIC.0b013e3283400cd3
更新日期:2011-01-01 00:00:00
abstract::The interaction between plasma concentrations of the tricyclic antidepressant amitriptyline and the metabolism of the new antipsychotic risperidone was studied in 12 patients with chronic schizophrenia. Each patient received 3 mg risperidone twice a day for 28 days. Amitriptyline was coadministered at doses of 50 mg/d...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/00004850-199705000-00004
更新日期:1997-05-01 00:00:00
abstract::The side effects of antipsychotic drugs have always been a major concern for clinicians and the appreciation of their importance in the treatment of schizophrenia has increased steadily over the years. Epidemiological studies as well as trials of the prevention and treatment of antipsychotic side effects are the conse...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:10.1097/00004850-199501005-00005
更新日期:1995-01-01 00:00:00
abstract::The effect of adjunctive fluoxetine on negative schizophrenic symptoms was evaluated in 34 chronic schizophrenic in-patients on maintenance therapy with neuroleptics. They received randomly, on a double-blind basis, fluoxetine (20 mg/day) or placebo for 12 weeks. In the fluoxetine group, three patients dropped out bec...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/00004850-199400940-00007
更新日期:1994-01-01 00:00:00
abstract::Data from the National Comorbidity Survey (NCS) general population study and the World Health Organization (WHO) primary care study have established that comorbidity between panic and depression is one of the strongest psychiatric associations. The two studies agree that patients with panic-depression comorbidity have...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:10.1097/00004850-199804004-00003
更新日期:1998-04-01 00:00:00
abstract::Neuroleptics are of established efficacy in mania. Controlled data on the use of olanzapine in mania is however, absent. In this study, 30 patients meeting DSM-IV criteria for mania were randomly allocated to receive either olanzapine or lithium in a 4 week double-blind randomized controlled design. There were no sign...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/00004850-199911000-00003
更新日期:1999-11-01 00:00:00
abstract::Body dysmorphic disorder (BDD) is a relatively common and impairing disorder. Selective serotonin reuptake inhibitors (SRIs) appear selectively efficacious for BDD, but pharmacotherapy research is limited, and escitalopram has not been studied. Fifteen subjects with BDD were treated with escitalopram and assessed with...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/01.yic.0000194378.65460.ef
更新日期:2006-05-01 00:00:00
abstract::The objective of this study was to examine the safety and tolerability of duloxetine hydrochloride, a serotonin-norepinephrine reuptake inhibitor, in a large cohort of elderly patients with major depressive disorder. Data were pooled from 8-week and 12-week, double-blind, randomized, placebo-controlled trials of dulox...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,meta分析
doi:10.1097/YIC.0b013e32835b09cd
更新日期:2013-01-01 00:00:00
abstract::The treatment of negative symptoms of schizophrenia presents a major clinical challenge. This review examines the evidence pertaining to the efficacy, tolerability and safety of adding selective serotonin reuptake inhibitors (SSRIs) to antipsychotic agents in the treatment of negative symptoms in schizophrenia. Import...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:10.1097/00004850-200311000-00001
更新日期:2003-11-01 00:00:00
abstract::The clinical trial programme of sertraline, a selective serotonin re-uptake inhibitor, has shown the drug to have a favourable safety and toleration profile. In contrast, the tricyclic antidepressant, amitriptyline, produced a significant level of side effects, particularly anticholinergic. The side-effect profile of ...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:10.1097/00004850-199112002-00007
更新日期:1991-12-01 00:00:00
abstract::This double-blind study was performed on 10 aged insomniac patients who received, during 15 days, either triazolam (0.25 mg) or zopiclone (7.5 mg) at bed time. This in-patient period was bounded by two ambulatory periods of 5 days each, and two in-patient periods of 3 days each, during which the patients received a pl...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:
更新日期:1990-04-01 00:00:00
abstract::It has been suggested that the atypical antipsychotic drugs may induce a rapid improvement in individuals with melancholic depression. This might reflect a specific or non-specific effect on mood and other parameters. To examine this issue, ten consecutive patients, for whom olanzapine augmentation was judged a clinic...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/00004850-200203000-00008
更新日期:2002-03-01 00:00:00
abstract::Premenstrual dysphoria (PMD) is a severe form of premenstrual syndrome, afflicting approximately 5% of all women of fertile age. The cardinal symptoms are irritability and anger. In addition, sadness, tension and carbohydrate craving are common complaints. The symptoms surface regularly between ovulation and menstruat...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:
更新日期:1999-05-01 00:00:00
abstract::The interactions between warfarin and antidepressants can have potentially serious consequences resulting from enhanced or reduced anticoagulant activity. Information about such interactions was obtained from a Medline and hand search of the published literature, and by directly contacting manufacturers. The different...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:10.1097/00004850-199803000-00006
更新日期:1998-03-01 00:00:00
abstract::We report that perospirone may have had positive effects on the obesity of three patients with schizophrenia and on the fasting blood sugar (FBS) and HbA1C of two of them who had type 2 diabetes mellitus. ...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/00004850-200401000-00008
更新日期:2004-01-01 00:00:00
abstract::We investigated the relative efficacy and tolerability of aripiprazole once monthly (AOM) versus paliperidone palmitate (PP) for treating schizophrenia. Extensive databases searches on short-term, placebo-controlled, randomized studies of AOM and PP were performed. Indirect treatment comparisons were performed between...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,meta分析,评审
doi:10.1097/YIC.0000000000000177
更新日期:2017-09-01 00:00:00
abstract::While most depressed patients are prescribed a selective serotonin reuptake inhibitor (SSRI) as an initial treatment, the use of SSRIs as a second or third-line treatment for depression is not as prevalent. This trial assessed the efficacy of sertraline for patients with treatment-resistant depression (TRD) or patient...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/00004850-200309000-00006
更新日期:2003-09-01 00:00:00